Published in Trends Pharmacol Sci on April 01, 2003
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Translational research in central nervous system drug discovery. NeuroRx (2005) 1.12
Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem Int (2007) 0.90
Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis. Cell Mol Neurobiol (2010) 0.87
Functional genomics and proteomics: application in neurosciences. J Neurol Neurosurg Psychiatry (2004) 0.80
Parkia biglobosa improves mitochondrial functioning and protects against neurotoxic agents in rat brain hippocampal slices. Biomed Res Int (2014) 0.77
Ropinirole alters gene expression profiles in SH-SY5Y cells: a whole genome microarray study. Braz J Med Biol Res (2016) 0.75
Systems Pharmacology Based Study of the Molecular Mechanism of SiNiSan Formula for Application in Nervous and Mental Diseases. Evid Based Complement Alternat Med (2016) 0.75
Flavonoids: some of the wisdom of sage? Br J Pharmacol (2004) 0.75
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem (2004) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Role of iron in neurodegenerative disorders. Top Magn Reson Imaging (2006) 1.40
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med (2004) 1.34
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem (2002) 1.30
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem (2004) 1.24
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci (2005) 1.23
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res (2006) 1.21
Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals (2005) 1.21
Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem (2010) 1.19
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 1.17
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr (2008) 1.12
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol (2010) 1.11
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol (2002) 1.10
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J (2005) 1.09
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res (2004) 1.08
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res (2009) 1.04
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis (2008) 1.04
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology (2004) 1.03
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2009) 1.03
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther (2008) 1.02
Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord (2006) 0.99
Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem (2006) 0.99
Redox imbalance. Cell Tissue Res (2004) 0.98
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J (2004) 0.98
Manganese corroles prevent intracellular nitration and subsequent death of insulin-producing cells. ACS Chem Biol (2009) 0.98
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett (2004) 0.97
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry (2009) 0.97
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med (2013) 0.95
Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol (2003) 0.95
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J (2007) 0.95
A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med (2007) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem (2002) 0.94
Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis (2011) 0.93
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy (2011) 0.92
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci (2004) 0.92
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J (2003) 0.92
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol (2007) 0.92
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res (2009) 0.92
Rasagiline in Parkinson's disease. N Engl J Med (2010) 0.92
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett (2002) 0.92
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res (2002) 0.91
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol (2004) 0.91
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem (2007) 0.91
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res (2007) 0.91
Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) (2002) 0.90
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases. J Neurochem (2007) 0.90
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J (2007) 0.90
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem (2003) 0.90
Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol (2010) 0.90
Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem (2006) 0.89
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord (2014) 0.89
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci (2005) 0.89
The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol (2005) 0.88
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem (2004) 0.88
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res (2003) 0.88
Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death. Free Radic Biol Med (2012) 0.88
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics (2009) 0.87
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem (2008) 0.87
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis (2006) 0.86
A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. J Biol Chem (2009) 0.86
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J (2006) 0.86
Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J Med Chem (2009) 0.86
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.86
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis (2010) 0.86
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem (2002) 0.85
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets (2012) 0.85
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci (2007) 0.85
Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res (2009) 0.84
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology (2002) 0.84
Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem Biophys Res Commun (2007) 0.84
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs (2006) 0.84
Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotox Res (2003) 0.84
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem (2009) 0.83
Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. Curr Alzheimer Res (2007) 0.83